Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 4:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 132 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo injection (intravenous solution) Clear all
Completed Phase 4 Interventional Results available

Anhedonia, Development, and Emotions: Phenotyping and Therapeutics

NCT05487885
View directory record Official record
Conditions
Depression, Anhedonia
Interventions
Continuous theta burst stimulation (cTBS), Positive Affect Training, Ketamine Injectable Solution
Device · Behavioral · Drug
Lead sponsor
Erika Forbes
Other
Eligibility
15 Years to 25 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 25, 2026, 4:18 PM EDT
Completed Phase 1Phase 2 Interventional

Safety, Efficacy, and Pharmacokinetics (PK) Study of Trans Sodium Crocetinate (TSC) in Patients With Intermittent Claudication

NCT00725881
View directory record Official record
Conditions
Intermittent Claudication
Interventions
Trans sodium crocetinate (TSC), 0.9% normal saline
Drug
Lead sponsor
Diffusion Pharmaceuticals Inc
Industry
Eligibility
40 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
7
States / cities
Birmingham, Alabama • Santa Rosa, California • Stanford, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2011 · Synced Sep 25, 2026, 4:18 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

NCT04746924
View directory record Official record
Conditions
Non-small Cell Lung Cancer, NSCLC
Interventions
Tislelizumab, Ociperlimab, Pembrolizumab, Placebo
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
669 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
9
States / cities
Fullerton, California • Los Angeles, California • Ocala, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 25, 2026, 4:18 PM EDT
Withdrawn Phase 2 Interventional

Treatment of Lung Injury From COVID-19 Infection With Intravenous Sodium Nitrite

NCT04401527
View directory record Official record
Conditions
COVID-19, Acute Respiratory Distress Syndrome, Acute Respiratory Failure
Interventions
Sodium Nitrite, Normal Saline
Drug
Lead sponsor
Hope Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
Tampa, Florida • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2020 · Synced Sep 25, 2026, 4:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous and Subcutaneous Single and Repeated Doses of SAR441344 in Healthy Adult Subjects

NCT05845996
View directory record Official record
Conditions
Healthy Volunteers
Interventions
SAR441344, placebo, Keyhole limpet hemocyanin
Drug · Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 45 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Sep 25, 2026, 4:18 PM EDT
Completed Phase 3 Interventional Results available

A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

NCT02549170
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Interventions
HYQVIA, 0.25% albumin placebo solution with rHuPH20, IGIV GAMMAGARD LIQUID/KIOVIG, IGIV GAMUNEX®-C
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
19
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Orange, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Sep 25, 2026, 4:18 PM EDT
Terminated Phase 3 Interventional Results available

Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT04419558
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Pamrevlumab, Placebo
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
40 Years to 85 Years
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
23
States / cities
Birmingham, Alabama • San Francisco, California • Denver, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2024 · Synced Sep 25, 2026, 4:18 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP)

NCT02985879
View directory record Official record
Conditions
Progressive Supranuclear Palsy
Interventions
Placebo, ABBV-8E12
Drug
Lead sponsor
AbbVie
Industry
Eligibility
40 Years and older
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
27
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Beverly Hills, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Sep 25, 2026, 4:18 PM EDT
Completed Phase 3 Interventional Results available

Follow up Study to Assess Long Term Safety and Outcomes in Infants and Children Born to Mothers Participating in Retosiban Treatment Studies

NCT02292784
View directory record Official record
Conditions
Obstetric Labour, Premature
Interventions
Retosiban, Atosiban, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
10 Weeks to 20 Weeks
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Park Ridge, Illinois • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Sep 25, 2026, 4:18 PM EDT
Completed Phase 3 Interventional

Re-EValuating the Inhibition of Stress Erosions (REVISE) Trial

NCT03374800
View directory record Official record
Conditions
Gastrointestinal Hemorrhage (Clinically Important, Upper)
Interventions
Placebo (0.9% saline), Pantoprazole
Drug
Lead sponsor
McMaster University
Other
Eligibility
18 Years and older
Enrollment
4,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Sep 25, 2026, 4:18 PM EDT
Not yet recruiting Phase 1 Interventional

OPT101 in Patients With Community Acquired Pneumonia (CAP) With Sepsis

NCT06669403
View directory record Official record
Conditions
Sepsis, Community Acquired Pneumonia (CAP)
Interventions
OPT101, Placebo
Drug · Other
Lead sponsor
Op-T LLC
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Sep 25, 2026, 4:18 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Bridging PK Profile of FB825 for Single Subcutaneous Administration in Healthy Adults

NCT05952986
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
FB825 or Placebo in subcutaneous route, FB825 in intravenous route
Drug
Lead sponsor
Oneness Biotech Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2024 · Synced Sep 25, 2026, 4:18 PM EDT
Withdrawn Phase 2 Interventional

Study To Evaluate D-Ribose For The Treatment of Congestive Heart Failure

NCT01858480
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
D-ribose, Placebo
Drug · Other
Lead sponsor
RiboCor, Inc.
Industry
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
20
States / cities
Long Beach, California • Modesto, California • Sylmar, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Sep 25, 2026, 4:18 PM EDT
Terminated Phase 2 Interventional Results available

Evaluation of FDY-5301 in Major Trauma Patients in ICU

NCT04430283
View directory record Official record
Conditions
ICU Acquired Weakness
Interventions
FDY-5301, Placebo
Drug · Other
Lead sponsor
Faraday Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Torrance, California • Gainesville, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Sep 25, 2026, 4:18 PM EDT
Completed Phase 2 Interventional Results available

Study of Abatacept Versus Placebo to Assess the Prevention of Rheumatoid Arthritis (RA) in Adult Patients

NCT00124449
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Abatacept, placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
20
States / cities
Huntsville, Alabama • Mobile, Alabama • Huntington Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Sep 25, 2026, 4:18 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes

NCT07167693
View directory record Official record
Conditions
Diabetes (DM), Diabetic Ketoacidosis, Ketosis Prone Diabetes, Hyperglycaemia (Diabetic)
Interventions
Arginine hydrochloride, Sodium Chloride 0.9%
Drug
Lead sponsor
David K Carroll
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 25, 2026, 4:18 PM EDT
Active, not recruiting Phase 3 Interventional

A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

NCT05933577
View directory record Official record
Conditions
Melanoma
Interventions
Intismeran autogene, Pembrolizumab, Placebo
Biological · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,089 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
34
States / cities
Springdale, Arkansas • Los Angeles, California • San Francisco, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Sep 25, 2026, 4:18 PM EDT
Terminated Phase 3 Interventional

A Phase 3 Clinical Trial of Intravenous Sodium Thiosulfate in Acute Calciphylaxis Patients

NCT03150420
View directory record Official record
Conditions
Calciphylaxis
Interventions
Sodium Thiosulfate, Placebo-Normal Saline
Drug
Lead sponsor
Hope Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
12
States / cities
Jacksonville, Florida • Chicago, Illinois • Maywood, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated May 18, 2020 · Synced Sep 25, 2026, 4:18 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Does Tranexamic Acid Decrease Blood Loss in Pediatric Idiopathic Scoliosis Surgery?

NCT01813058
View directory record Official record
Conditions
Adolescent Idiopathic Scoliosis
Interventions
Tranexamic Acid, Placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
10 Years to 21 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 19, 2019 · Synced Sep 25, 2026, 4:18 PM EDT
Suspended Phase 3 Interventional

Ketorolac Applied by Continuous IV Infusion for Treatment of Moderately Severe Postoperative Pain Following Bunionectomy

NCT05324358
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Ketorolac Tromethamine, Morphine Sulfate, Intravenous Placebo for NTM-001, IV Placebo for Morphine
Drug · Other
Lead sponsor
Neumentum, Inc.
Other
Eligibility
18 Years to 64 Years
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
10
States / cities
Sun City, Arizona • Bakersfield, California • Canoga Park, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 25, 2026, 4:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Staccato® Granisetron Single Dose PK

NCT04200092
View directory record Official record
Conditions
Healthy
Interventions
0.5mg AZ-010; placebo, 1mg AZ-010, 3mg AZ-010, AZ-010 1mg, IV Granisetron 1mg, Placebo
Combination Product · Drug · Other
Lead sponsor
Nova Pneuma Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 25, 2026, 4:18 PM EDT
Terminated Phase 3 Interventional Results available

To Compare Safety and Efficacy of Doripenem Versus Imipenem-Cilastatin in Patients With Ventilator-Associated Pneumonia

NCT00589693
View directory record Official record
Conditions
Ventilator-Associated Pneumonia
Interventions
Doripenem, Imipenem-Cilastatin, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
17
States / cities
Jonesboro, Arkansas • Newark, Delaware • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2012 · Synced Sep 25, 2026, 4:18 PM EDT
Completed Phase 4 Interventional Results available

Oral Versus Intravenous Sedation for Ocular Procedures

NCT03246724
View directory record Official record
Conditions
Surgery, Sedation
Interventions
Triazolam, Midazolam, Microcrystalline Cellulose, Sodium chloride 0.9%
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Sep 25, 2026, 4:18 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)

NCT01212094
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Rituximab, normal saline
Drug · Other
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 27, 2016 · Synced Sep 25, 2026, 4:18 PM EDT